Show simple item record

dc.contributor.authorGujral, DM
dc.contributor.authorLong, M
dc.contributor.authorRoe, JWG
dc.contributor.authorHarrington, KJ
dc.contributor.authorNutting, CM
dc.date.accessioned2017-04-10T15:17:39Z
dc.date.issued2017-01-01
dc.identifier.citationClinical oncology (Royal College of Radiologists (Great Britain)), 2017, 29 (1), pp. 42 - 50
dc.identifier.issn0936-6555
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/569
dc.identifier.eissn1433-2981
dc.identifier.doi10.1016/j.clon.2016.09.017
dc.description.abstractAIMS: Recently, carotid-sparing intensity-modulated radiotherapy (IMRT) for early laryngeal glottis (T1/T2N0M0) cancer has generated interest in the hope of avoiding long-term carotid toxicity, as well as concerns relating to geographical misses and long-term normal tissue toxicity. The aim of this review was to summarise the current literature on carotid-sparing IMRT for early glottis cancer, with particular focus on definitions of target volumes and the carotid arteries as organs at risk. In addition, we make suggestions for standardisation of these structures, dose constraints and dose reporting. MATERIALS AND METHODS: From 73 references, 16 articles met the criteria for inclusion in this systematic review. These papers described two case reports, 11 planning studies and three prospective studies. RESULTS: There was variation in all target volume definitions with no clear consensus. The greatest variability was in clinical target volume definition. Carotid artery and spinal cord delineation were not always defined and most studies did not use a carotid artery constraint. Of the eight studies that reported carotid artery delineation, no two studies delineated the same length of carotid artery, yet most studies reported mean doses. Most studies used IMRT with three to seven fields. Five studies used arc therapy and two studies used tomotherapy. CONCLUSION: This review highlights a lack of consensus in target volume definitions in carotid-sparing IMRT. Ultimately, long-term prospective data are required to show the benefit of carotid-sparing IMRT. Pooled data will prove useful as most studies will report on small numbers of patients. Therefore, adopting a consensus now on target volume definition, dose constraints and dose reporting will be crucial.
dc.formatPrint-Electronic
dc.format.extent42 - 50
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCIENCE LONDON
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectGlottis
dc.subjectCarotid Arteries
dc.subjectHumans
dc.subjectLaryngeal Neoplasms
dc.subjectRadiotherapy, Conformal
dc.subjectRadiotherapy Dosage
dc.subjectRadiotherapy Planning, Computer-Assisted
dc.subjectProspective Studies
dc.subjectMale
dc.subjectRadiotherapy, Intensity-Modulated
dc.titleStandardisation of Target Volume Delineation for Carotid-sparing Intensity-modulated Radiotherapy in Early Glottis Cancer.
dc.typeJournal Article
dcterms.dateAccepted2016-08-31
rioxxterms.versionofrecord10.1016/j.clon.2016.09.017
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical oncology (Royal College of Radiologists (Great Britain))
pubs.issue1
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume29
pubs.embargo.terms12 months
icr.researchteamTargeted Therapy
dc.contributor.icrauthorHarrington, Kevin


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record